Merck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion

The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist. The deal is Merck’s largest since 2015, when it spent $17bn on acquiring Sigma-Aldrich, also a life sciences specialist. The acquisition marks the first under the watch of new CEO Kai Beckmann, who took the helm in September 2025. Credit: Kittyfly/Shutterstock.com. Merck KGaA has agreed to acquire life sciences company Bio-Techne Corporation for $11.3bn, representing one of the largest financial outlays by a drugmaker so far this year. As per the deal, Merck will pay $73 for each of Bio-Techne’s US-listed…

Source: Medical Device Network